Local Medical Device Company, NuVasive(R), Sponsors the 6th Annual San Diego Festival of Science and Engineering Expo Day

Marketwired
Local Medical Device Company, NuVasive(R), Sponsors the 6th Annual San Diego Festival of Science and Engineering Expo Day
.

View photo

As a local medical device company that is a global leader in minimally invasive surgery, NuVasive is …

SAN DIEGO, CA--(Marketwired - Mar 21, 2014) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to sponsor the 6th Annual San Diego Festival of Science and Engineering EXPO Day on Saturday, March 22, 2014 from 10:00 a.m. to 5:00 p.m. at PETCO Park, booths #P10 and P12.

The San Diego Festival of Science and Engineering EXPO Day is the city's largest celebration of science, offering thousands of students and their families the opportunity to "excite their minds" with more than 100 hands-on interactive science experiments.

As a local medical device company that is a global leader in minimally invasive surgery, NuVasive is passionate about encouraging children of all ages to explore the fields of Science, Technology, Engineering and Math (STEM) to further their interest in innovation.

"EXPO day is a great opportunity for young children and adults to explore the possibilities of innovation," said Alex Lukianov, NuVasive Chairman and Chief Executive Officer. "As a parent myself, I am excited to introduce children to the power of science and to demonstrate the life-changing capabilities that it can have. In our mission to change spine surgery, we rely heavily on science to constantly invent new and innovative technology that can improve patient lives and surgical outcomes."

Over the last decade, NuVasive has built a procedurally integrated portfolio with more than 90 products and procedures that address all areas of the spine, spanning lumbar, thoracic, and cervical applications.

The Company has changed hundreds of thousands of patient lives with game-changing solutions like the eXtreme Lateral Interbody Fusion (XLIF®) procedure. The XLIF procedure is an innovative approach for spine fusion, which accesses the spine from the side of the body as opposed to traditional fusions, which access the spine from the patient's front or back. The XLIF approach can reduce trauma to the patient and has the potential to treat pathologies that could not previously be treated.

XLIF patients are often able to walk the same day of surgery, suffer less blood loss, spend less time in the hospital, and are back to their daily activities within four to six weeks. By comparison, a traditional "open" spine fusion surgery typically requires a larger incision, resulting in significantly longer recovery times and increased blood loss.

As a supporter of STEM programs, NuVasive prides itself in continually making progress to improve patient lives through innovation and game-changing technology.

Click here to learn more about NuVasive or search employment opportunities.

About the San Diego Science Festival:

The San Diego Science Festival is a year-round organization that celebrates San Diego as one of the nation's leading Science & Engineering Regions. The organization's goal is to promote science education in San Diego by bringing together community and corporate leaders to provide programming and pre-workforce development opportunities for our next generation of scientists.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive® is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

About XLIF®
The XLIF procedure, like any other surgical procedure, is not without risks. Possible complications include, but are not limited to: persistent pain, infection, muscle weakness, vascular injury (injury of the blood vessels), neurologic (nerve or spinal cord) injury, urinary tract infection, stroke, pneumonia, deep vein thrombosis (clotting), and further progression of existing spinal disease. A discussion detailing all potential risks of the XLIF procedure, or any procedure, should take place between patient and physician.

Spine surgeries, including the XLIF procedure, carry inherent risks and potential complications, which should be discussed between patient and surgeon. Complications vary in severity, including the possibility of death, and can result from surgery in general (e.g., infection or bleeding requiring transfusion), from the approach to the pathology (e.g., vascular, organ or other soft-tissue injury, or injuries to the motor or sensory nerves), spine surgery related complications (e.g., re-operation required for malpositioned hardware or inadequate decompression) and medical related issues (e.g., due to other co-morbidities such as diabetes, heart disease, lung disease, use of steroids, and/or smoking).

Complications can also manifest later in the postoperative period, which may require additional procedures (e.g., delayed wound healing, infection, migration or failure of the implants, fracture or settling of the bone, failed fusion).

It is important to reiterate that planning for spine surgery should include detailed discussion between patient and surgeon concerning potential complications associated with current spine surgery treatment options.

The information provided in this press release is for general educational information only. Information you read in this press release cannot replace the relationship that you have with your healthcare professional. We do not practice medicine or provide medical or advice as part of this press release. You should also talk to your healthcare professional for diagnosis and treatment.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact:
Investor
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact

Media
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact

Rates

View Comments (0)